Earnings call transcript: Bruker Q2 2025 misses forecasts, stock drops

Bruker Corporation (BRKR) reported a significant Q2 2025 earnings miss, with EPS of $0.32 falling 23.81% below forecasts and revenue of $797.4 million also missing expectations, prompting a 15.11% stock decline in pre-market trading. The underperformance stems from pressures in the life science research instruments market, delayed China stimulus, and broader economic uncertainties. In response, Bruker has initiated an aggressive cost-saving program targeting €100-120 million in annual reductions, mainly impacting FY2026, and consequently lowered its FY2025 organic revenue guidance to a 2-4% decline and non-GAAP EPS to $1.95-$2.05, though management remains optimistic for a substantial EPS rebound in 2026 driven by these cost efficiencies.

Analysis

Bruker Corporation (BRKR) reported a significant underperformance in its second quarter of 2025, with earnings per share of $0.32 missing forecasts by 23.81% and revenue of $797.4 million falling 1.9% short of expectations. The negative results, which triggered a 15.11% pre-market stock decline, were driven by a 7% organic revenue contraction stemming from broad-based market headwinds, including delayed capital expenditures in biopharma and industrial research, persistent funding challenges in U.S. academia, and postponed stimulus for high-end instrumentation in China. This top-line weakness, coupled with impacts from tariffs and foreign exchange, compressed the non-GAAP operating margin by 480 basis points year-over-year to 9%. In response, management has lowered its full-year 2025 guidance, now projecting an organic revenue decline of 2-4% and a non-GAAP EPS of $1.95-$2.05. The core of the forward-looking strategy now rests on an aggressive cost-reduction initiative targeting €100-120 million in annualized savings, which the company expects will drive significant margin expansion and a double-digit EPS rebound in 2026, even in a muted or no-growth revenue scenario.

Key Decisions for Investors

• Investors should recognize that the near-term outlook for Bruker is challenging, as reflected in the sharply reduced fiscal 2025 guidance and the stock trading near its 52-week low.
• The investment thesis now hinges on a 2026 turnaround; closely monitor the execution and impact of the announced €100-120 million cost-saving program, which management presents as the primary driver for significant margin and EPS growth.
• Consider the current stock price as a potential value entry point, but weigh this against considerable execution risk and market uncertainty, particularly in the life sciences and China end-markets.
• Key external catalysts to watch for include any stabilization in biopharma capital spending, resolution of U.S. academic funding, and the release of Chinese stimulus, as these would provide upside to the company's base case for 2026.